Skip to main content

Table 2 Frequency of TAGLN hypermethylation in tumor and normal breast tissues

From: Transgelin gene is frequently downregulated by promoter DNA hypermethylation in breast cancer

Study

Analyzed CpGs

Cohort

Hypermethylatedc

Hypomethylatedd

Matched tumor tissue panel (bisulfite sequencing)a

−290 to +117

All patients (n = 21)

13 (61.90 %)

4 (19.05 %)

22 CpGs

Grade 1 (n = 5)

5 (100.00 %)

0 (0.00 %)

Grade 2 (n = 11)

6 (54.55 %)

3 (27.27 %)

Grade 3 (n = 2)

1 (50.00 %)

1 (50.00 %)

GSE20713 Methylation data (microarray analysis)b

−571 and 455

All patients (n = 338)

213 (63.02 %)

3 (0.89 %)

2 CpGs

Grade 1 (n = 64)

41 (64.06 %)

0 (0.00 %)

Grade 2 (n = 57)

35 (61.40 %)

1 (1.75 %)

Grade 3 (n = 215)

135 (62.79 %)

2 (0.01 %)

  1. aNumber of tumors were calculated based on average methylation ratio of 22 CpGs in our normal matched tumor tissues
  2. bNumber of tumors were calculated based on average methylation scores of two probes corresponding to two CpGs at given locations
  3. cNumber of tumors that are significantly hypermethylated in normal matched tumor tissue panel (P < 0.05, Wilcoxon signed rank test). In microarray methylation data, tumors with normalized average methylation score (NAMS) >30 higher than the average normal tissue NAMS were considered hypermethylated
  4. dNumber of tumors that are significantly hypomethylated in normal matched tumor tissue panel (P < 0.05, Wilcoxon signed rank test). In microarray methylation data, tumors with NAMS >30 lower than the average normal tissue NAMS were considered hypomethylated